RTI Surgical™ Celebrates First Human Implantation of map3™ Cellular Allogeneic Bone Graft

  RTI Surgical™ Celebrates First Human Implantation of map3™ Cellular
  Allogeneic Bone Graft

Business Wire

ALACHUA, Fla. -- August 12, 2013

RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, is
pleased to announce that the first human implantation of the company’s map3™
Cellular Allogeneic Bone Graft implant was completed last week.

Dr. Franco E. Vigna, M.D., M.P.H., a board-certified orthopedic surgeon with
Spine Surgery of Buffalo Niagara and a fellow with American Academy of
Orthopaedic Surgeons, performed the first implantation during a spinal surgery
in New York. He used the implant’s chips allograft configuration, one of two
configurations that will be available once the implant launches.

“I am excited to have map3 as an option for my patients because of its
specific osteogenic and angiogenic properties,” said Vigna, who has been
honored as one of the top American orthopedists in spinal care, according to
the Consumers’ Research Council of America, 2009. “The future of spine surgery
is biologics. We can place the best metal implants but if the bony fusion does
not take place, those implants will loosen and the fusion will fail. Having
top quality natural biologics along with excellent metal implants gives
physicians and patients the best of both worlds.”

Map3 cellular allogeneic bone graft is a natural and safe alternative to
autograft. Map3 provides a streamlined approach to bone grafting and supplies
the three elements necessary for bone repair—osteogenesis, osteoinduction and
osteoconduction—in a single allograft. Map3 incorporates multipotent adult
progenitor cell-based (MAPC™-based) technology with stem cells isolated from
the same donor as the other bone material. The MAPC technology, licensed from
Athersys, Inc. for this orthopedic application, represents a distinctive type
of stem cell with recognized angiogenic and immuno-modulatory properties. Once
launched, map3 will be available in multiple configurations and sizes,
providing bone grafting options for various bone repair, reconstruction and
fusion procedures.

“We are thrilled to reach this milestone for map3,” said Brian K. Hutchison,
RTI president and CEO. “The MAPC-based technology offers the greatest
potential to create high quality, innovative implants for our surgeons and
their patients and will greatly enhance our company’s orthobiologics
offerings. We anticipate a market release of the implant later this year.”

Surgeons can learn more about the implant and RTI’s other offerings at the
North American Spine Society’s (NASS) Annual Meeting in New Orleans, Oct.
9-12. RTI will be exhibiting at booth #621.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons
with safe biologic, metal and synthetic implants. Committed to advancing
science, safety and innovation, RTI’s implants are used in sports medicine,
general surgery, spine, orthopedic, trauma and cardiothoracic procedures and
are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla.,
and has four manufacturing facilities throughout the U.S. and Europe.RTI is
accredited in the U.S. by the American Association of Tissue Banks and is a
member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s current expectations, estimates and
projections about our industry, our management's beliefs and certain
assumptions made by our management. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," variations of such words
and similar expressions are intended to identify such forward-looking
statements. In addition, except for historical information, any statements
made in this communication about anticipated financial results, growth rates,
new product introductions, future operational improvements and results or
regulatory actions or approvals or changes to agreements with distributors
also are forward-looking statements. These statements are not guarantees of
future performance and are subject to risks and uncertainties, including the
risks described in public filings with the U.S. Securities and Exchange
Commission (SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements. Copies of
the company's SEC filings may be obtained by contacting the company or the SEC
or by visiting RTI's website at www.rtix.com or the SEC's website at
www.sec.gov.

Contact:

RTI Surgical Inc.
Jenny Highlander, APR, 386-418-8888, ext. 4149
Manager, Corporate Communications
jhighlander@rtix.com
 
Press spacebar to pause and continue. Press esc to stop.